Analysis of oOh!media, Cochlear, Elders
Fund Manager Chris Pedersen discusses oOh!media, Cochlear and Elders.
Read More
Cochlear Limited
We help people hear and be heard. We empower people to connect with others and live a full life.
We help transform the way people understand and treat hearing loss.
We innovate and bring to market a range of implantable hearing solutions that deliver a lifetime of hearing outcomes.
Spotlight Videos
Analysis of oOh!media, Cochlear, Elders
Fund Manager Chris Pedersen discusses oOh!media, Cochlear and Elders.
WATCH VIDEOAll Cochlear Limited Content
News
Cochlear surpasses expectations
Earlier this month, hearing implant giant Cochlear surprised investors with a significant upgrade to revenue growth and earnings for the six months to December, along with higher guidance for the year to June 30. Today, it has followed up with the actual figures for the six months to December, along with a higher dividend.
Read More
Companies immune from rate rises: Sonic Healthcare, Cochlear, Transurban
Fund Manager Chris Pedersen discusses the RBA's rate hike, inflation, banks, dividend growth stocks, Sonic Healthcare, Transurban Group and Cochlear.
Read More
Cochlear anticipates robust performance for 2023-24
Hearing device manufacturer, Cochlear (ASX:COH), is poised for a strong performance in the fiscal year 2023-24, following a commendable performance until June.
Read More
Corporate Chatter: TWE, COH, VCX
A veritable plethora of earnings reports through the ASX today, from which we have sifted those by Treasury Wine Estates, Cochlear and Vicinity Centres for your consideration.
Read More
Analyst Views
COH – Morgans rates the stock as Hold
While FY21 results were below consensus, they were in-line with Morgans expectations while guidance points to continued momentum. The Hold rating is unchanged and the target price increases to $214.5 from $201.1.
Read More
COH – Credit Suisse rates the stock as Neutral
The Neutral rating is unchanged and the target falls to $225 from $230.
Read More
COH – UBS rates the stock as Sell
UBS assumes a less favourable cost leverage scenario than the market, and consequently values Cochlear -10% below the current share price.
Read More
COH – UBS rates the stock as Sell
UBS is not surprised by the company's decision to raise up to $850m, considering the sudden deterioration in the operating environment and the likelihood of paying out $380m in penalties following the lost patent infringement case.
Read More
COH – Morgans rates the stock as Hold
FY20 profit guidance is downgraded by up to -7% because of the impact of coronavirus in greater China. Management has not witnessed any impact outside of greater China and is not making any changes to the cost base.
Read More
